文献速递白血病

Iadademstat(ORY-1001)治疗复发难治性急性髓系白血病的首次人体I期研究

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.
PubMed 文献 · J Clin Oncol · 2020-10-14

确定推荐剂量为140 µg/m2/d,总体安全性良好,并观察到临床与生物学活性迹象,尤其在MLL重排患者中诱导 blast 分化。

要点

  • Iadademstat单药推荐剂量为140 µg/m2/d,每28天周期第1-5天给药。
  • 多数不良事件为复发难治性AML预期事件,包括骨髓抑制、感染、乏力、黏膜炎和腹泻。
  • 在MLL重排患者中观察到血液和骨髓原始细胞比例下降及分化诱导。

核心结论

  • Iadademstat单药在复发难治性AML患者中显示出良好的安全性及临床和生物学活性迹象。

主要发现

  • 剂量递增阶段(5-220 µg/m2/d,每28天周期第1-5天)确定单药推荐剂量为140 µg/m2/d。
  • 扩展队列纳入14例患者,富集MLL/KMT2A重排AML。
  • 药代动力学显示血浆暴露随剂量增加,药效学证实时间与暴露依赖的分化标志物诱导。
  • 在MLL易位患者中观察到血液和骨髓原始细胞比例下降及原始细胞分化诱导。
  • 剂量递增组观察到1例完全缓解伴计数不完全恢复。

关键数值与推荐

  • 推荐剂量为140 µg/m2/d,单药每28天周期第1-5天给药。

临床怎么用

  • Iadademstat单药在复发难治性AML中具有可管理的安全性,支持进一步联合阿扎胞苷的II期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro and in vivo antileukemic activity. This study aimed to determine safety and tolerability of iadademstat as monotherapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML). METHODS: This phase I, nonrandomized, open-label, dose-escalation (DE), and extension-cohort (EC) trial included patients with R/R AML and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic activity of this orally bioavailable first-in-class lysine-specific demethylase 1 inhibitor. RESULTS: Twenty-seven patients were treated with iadademstat on days 1 to 5 (5-220 µg/m2/d) of each week in 28-day cycles in a DE phase that resulted in a recommended dose of 140 µg/m2/d of iadademstat as a single agent. This dose was chosen to treat all patients (n = 14) in an EC enriched with patients with MLL/KMT2A-rearranged AML. Most adverse events (AEs) were as expected in R/R AML and included myelosuppression and nonhematologic AEs, such as infections, asthenia, mucositis, and diarrhea. PK data demonstrated a dose-dependent increase in plasma exposure, and PD data confirmed a potent time- and exposure-dependent induction of differentiation biomarkers. Reductions in blood and bone marrow blast percentages were observed, together with induction of blast cell differentiation, in particular, in patients with MLL translocations. One complete remission with incomplete count recovery was observed in the DE arm. CONCLUSION: Iadademstat exhibits a good safety profile together with signs of clinical and biologic activity as a single agent in patients with R/R AML. A phase II trial of iadademstat in combination with azacitidine is ongoing (EudraCT No.: 2018-000482-36).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Salamero O, Montesinos P, Willekens C, et al. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2020. PMID: 33052756. doi:10.1200/JCO.19.03250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。